160 related articles for article (PubMed ID: 22435971)
1. Calpain-2 expression is associated with response to platinum based chemotherapy, progression-free and overall survival in ovarian cancer.
Storr SJ; Safuan S; Woolston CM; Abdel-Fatah T; Deen S; Chan SY; Martin SG
J Cell Mol Med; 2012 Oct; 16(10):2422-8. PubMed ID: 22435971
[TBL] [Abstract][Full Text] [Related]
2. Calpain system protein expression and activity in ovarian cancer.
Zhang S; Deen S; Storr SJ; Chondrou PS; Nicholls H; Yao A; Rungsakaolert P; Martin SG
J Cancer Res Clin Oncol; 2019 Feb; 145(2):345-361. PubMed ID: 30448882
[TBL] [Abstract][Full Text] [Related]
3. Calpain-1 expression is associated with relapse-free survival in breast cancer patients treated with trastuzumab following adjuvant chemotherapy.
Storr SJ; Woolston CM; Barros FF; Green AR; Shehata M; Chan SY; Ellis IO; Martin SG
Int J Cancer; 2011 Oct; 129(7):1773-80. PubMed ID: 21140455
[TBL] [Abstract][Full Text] [Related]
4. Expression of the calpain system is associated with poor clinical outcome in gastro-oesophageal adenocarcinomas.
Storr SJ; Pu X; Davis J; Lobo D; Reece-Smith AM; Parsons SL; Madhusudan S; Martin SG
J Gastroenterol; 2013 Nov; 48(11):1213-21. PubMed ID: 23329366
[TBL] [Abstract][Full Text] [Related]
5. Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.
García-Sáenz JA; Custodio A; Casado A; Vidart JA; Coronado PJ; Martín M; López-Tarruella S; Puente J; Fernández C; Díaz-Rubio E
Clin Transl Oncol; 2011 Feb; 13(2):121-32. PubMed ID: 21324801
[TBL] [Abstract][Full Text] [Related]
6. [Recurrence risk factors of platinum-sensitive epithelial ovarian cancer].
Yan XJ; Liang LZ; Zeng ZY; Liu JH; Yuan SH; Wei M
Ai Zheng; 2005 Jun; 24(6):751-4. PubMed ID: 15946495
[TBL] [Abstract][Full Text] [Related]
7. The calpain system is associated with survival of breast cancer patients with large but operable inflammatory and non-inflammatory tumours treated with neoadjuvant chemotherapy.
Storr SJ; Zhang S; Perren T; Lansdown M; Fatayer H; Sharma N; Gahlaut R; Shaaban A; Martin SG
Oncotarget; 2016 Jul; 7(30):47927-47937. PubMed ID: 27323818
[TBL] [Abstract][Full Text] [Related]
8. Clinical response to antiestrogen therapy in platinum-resistant ovarian cancer patients and the role of tumor estrogen receptor expression status.
Stasenko M; Plegue M; Sciallis AP; McLean K
Int J Gynecol Cancer; 2015 Feb; 25(2):222-8. PubMed ID: 25500503
[TBL] [Abstract][Full Text] [Related]
9. Calpain system protein expression in carcinomas of the pancreas, bile duct and ampulla.
Storr SJ; Zaitoun AM; Arora A; Durrant LG; Lobo DN; Madhusudan S; Martin SG
BMC Cancer; 2012 Nov; 12():511. PubMed ID: 23140395
[TBL] [Abstract][Full Text] [Related]
10. A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy.
Kang J; D'Andrea AD; Kozono D
J Natl Cancer Inst; 2012 May; 104(9):670-81. PubMed ID: 22505474
[TBL] [Abstract][Full Text] [Related]
11. ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance.
Kuhlmann JD; Wimberger P; Bankfalvi A; Keller T; Schöler S; Aktas B; Buderath P; Hauch S; Otterbach F; Kimmig R; Kasimir-Bauer S
Clin Chem; 2014 Oct; 60(10):1282-9. PubMed ID: 25015375
[TBL] [Abstract][Full Text] [Related]
12. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
[TBL] [Abstract][Full Text] [Related]
13. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
14. Malignant mixed mullerian tumour of the ovary: prognostic factor and response of adjuvant platinum-based chemotherapy.
Inthasorn P; Beale P; Dalrymple C; Carter J
Aust N Z J Obstet Gynaecol; 2003 Feb; 43(1):61-4. PubMed ID: 12755351
[TBL] [Abstract][Full Text] [Related]
15. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery: A multicenter cohort analysis from the FRANCOGYN study group.
Vincent L; Jankowski C; Ouldamer L; Ballester M; Bendifallah S; Bolze PA; Akladios C; Costaz H; Lavoué V; Canlorbe G; Collinet P; Touboul C; Huchon C; Bricou A; Dridi S; Padéano MM; Bengrine L; Arnould L; Coutant C;
Eur J Surg Oncol; 2020 Sep; 46(9):1689-1696. PubMed ID: 32417154
[TBL] [Abstract][Full Text] [Related]
17. Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.
Pignata S; Ferrandina G; Scarfone G; Scollo P; Odicino F; Cormio G; Katsaros D; Frigerio L; Mereu L; Ghezzi F; Manzione L; Lauria R; Breda E; Alletti DG; Ballardini M; Vernaglia A; Sorio R; Tumolo S; Musso P; Magni G; Pisano C; Morabito A
Crit Rev Oncol Hematol; 2009 Sep; 71(3):233-41. PubMed ID: 19179095
[TBL] [Abstract][Full Text] [Related]
18. Expression of Syk and MAP4 proteins in ovarian cancer.
Zhang S; Deen S; Storr SJ; Yao A; Martin SG
J Cancer Res Clin Oncol; 2019 Apr; 145(4):909-919. PubMed ID: 30737623
[TBL] [Abstract][Full Text] [Related]
19. HPIP expression predicts chemoresistance and poor clinical outcomes in patients with epithelial ovarian cancer.
Wang Y; Li M; Meng F; Lou G
Hum Pathol; 2017 Feb; 60():114-120. PubMed ID: 27818289
[TBL] [Abstract][Full Text] [Related]
20. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Pujade-Lauraine E; Fujiwara K; Ledermann JA; Oza AM; Kristeleit R; Ray-Coquard IL; Richardson GE; Sessa C; Yonemori K; Banerjee S; Leary A; Tinker AV; Jung KH; Madry R; Park SY; Anderson CK; Zohren F; Stewart RA; Wei C; Dychter SS; Monk BJ
Lancet Oncol; 2021 Jul; 22(7):1034-1046. PubMed ID: 34143970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
